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Chlamydia trachomatis invasion of eukaryotic host cells is facilitated, in part, by the type
III secreted effector protein, Tarp. The role of Tarp in chlamydiae entry of host cells is
supported by molecular approaches that examined recombinant Tarp or Tarp effectors
expressed within heterologous systems. A major limitation in the ability to study the
contribution of Tarp to chlamydial invasion of host cells was the prior absence of genetic
tools for chlamydiae. Based on our knowledge of Tarp domain structure and function
along with the introduction of genetic approaches in C. trachomatis, we hypothesized
that Tarp function could be disrupted in vivo by the introduction of dominant negative
mutant alleles. We provide evidence that transformed C. trachomatis produced epitope
tagged Tarp, which was secreted into the host cell during invasion. We examined
the effects of domain specific Tarp mutations on chlamydial invasion and growth and
demonstrate thatC. trachomatis clones harboring engineered Tarpmutants lacking either
the actin binding domain or the phosphorylation domain had reduced levels of invasion
into host cells. These data provide the first in vivo evidence for the critical role of Tarp in
C. trachomatis pathogenesis and indicate that chlamydial invasion of host cells can be
attenuated via the introduction of engineered dominant negative type three effectors.
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INTRODUCTION
Chlamydia trachomatis is an obligate intracellular bacterium responsible for many human diseases
(Moulder et al., 1984). Distinct serovars are the etiologic agents of endemic blinding trachoma,
sexually transmitted disease, and lymphogranuloma venereum (Byrne, 2010). Chlamydiae
undergo a unique developmental cycle consisting of two metabolically and morphologically
distinct developmental forms adapted for extracellular survival and intracellular multiplication,
respectively (Swanson et al., 1975; Szaszak et al., 2011; Omsland et al., 2012). Elementary bodies
(EBs) are small, metabolically dormant cell types that actively promote invasion of eukaryotic host
cells (Carabeo et al., 2002). Reticulate bodies (RBs) are larger cell types that are metabolically active
and undergo replication (Omsland et al., 2012). EBs differentiate into RBs within the first few hours
following infection. The RBs thenmultiply by binary fission until∼16–24 h post-infection, at which
time they asynchronously begin to differentiate back into EBs prior to release from the host cell and
initiation of subsequent rounds of infection (Moulder et al., 1984).
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Like many Gram-negative pathogens, chlamydiae have a type
III secretion system (T3SS) which they utilize to translocate
various effector proteins into the cytosol of the host cell.
Additionally, some secreted effectors localize to the expanding
inclusion membrane and are collectively referred to as the
Inc., proteins (Coburn et al., 2007). The chlamydial T3SS
functions in at least two distinct locations and times during
chlamydial development (Muschiol et al., 2006; Betts-Hampikian
and Fields, 2010; Case et al., 2010). One pool of early effectors,
pre-existing in EBs, is secreted upon contact with a host
cell without a requirement for chlamydial protein synthesis
(Jamison and Hackstadt, 2008; Valdivia, 2008). Later in the
developmental cycle, other effectors are secreted out toward
the cytosol from within the inclusion after initiation of protein
synthesis (Wolf et al., 2006). The translocated actin-recruiting
phosphoprotein (Tarp) is one of the early effectors and is
spatially and temporally associated with the recruitment of
actin to the site of EB invasion (Clifton et al., 2004). Tarp
is phosphorylated upon translocation into eukaryotic cells
by host tyrosine kinases (Jewett et al., 2008; Mehlitz et al.,
2008). All isolates of pathogenic Chlamydia examined to date
harbor the tarP gene (Clifton et al., 2005; Lutter et al., 2010).
Biochemical analysis of C. trachomatis Tarp and other Tarp
orthologs revealed that Tarp is comprised of an actin nucleating
domain which is conserved and a tyrosine-rich repeat domain
that is specific to serovars of C. trachomatis (Clifton et al.,
2005; Jewett et al., 2006, 2010). Tarp associates directly with
both globular (G-) and filamentous (F-) actin via small alpha
helical domains contained within the C-terminal region of the
protein (Jewett et al., 2006, 2010; Jiwani et al., 2013). Tarp’s
ability to directly bind to actin contributes to two biochemically
characterized functions, actin nucleation and actin bundling,
which likely lead to cytoskeletal modifications in the target
host cell during entry (Jewett et al., 2006; Jiwani et al., 2013).
Tarp independently nucleates new actin filaments by forming
a large homogenous multimeric protein complex mediated
by a conserved proline rich domain (Jewett et al., 2006).
Inhibition of the actin binding alpha helix with microinjected
antibodies specific for the Tarp actin binding domain blocked
Tarp-mediated actin polymerization in vitro and reduced C.
trachomatis L2 entry into host cells, suggesting Tarp is a critical
virulence factor associated with chlamydial invasion (Jewett et al.,
2010).
Although the direct actin-nucleating potential of C.
trachomatis Tarp is implicated in bacterial entry of host
cells, other actin nucleating pathways involving activation of
the Arp2/3 complex are also necessary for entry (Carabeo
et al., 2007; Jewett et al., 2010). Interestingly, phosphorylated
Tarp may also play a role by indirectly activating the Arp2/3
complex as Tarp immunoprecipitation and peptide array assays
have identified host cell signaling proteins such as Eps8, Rac1,
Abi1, Sos1, Vav2, and SHC1 that associate with phosphorylated
Tarp and promote Arp2/3 activation (Lane et al., 2008; Mehlitz
et al., 2010). Biochemically, the actin nucleating properties of
Tarp and the Arp2/3 complex work together to rapidly form
actin filaments required for internalization (Jiwani et al., 2012).
However, the precise details of how these distinct pathways
cooperate to promote chlamydial internalization still remains
unclear.
Since the Tarp effector has been characterized by various
cellular and molecular approaches, and is implicated in
chlamydial invasion of host cells, we sought to engineer
mutant Tarp effectors that would biochemically interfere with
endogenous Tarp function in vivo. In this work we examined
C. trachomatis transformants expressing epitope tagged mutant
Tarp alleles for their ability to invade host cells. Here, we report
that EBs which secrete mutant Tarp effectors harboring specific
domain deletions are deficient in bacterial entry of host cells. As
hypothesized, those EBs which expressed a mutant Tarp lacking
the actin binding domain, required for actin nucleation, were
attenuated for bacterial invasion of host cells. Interestingly, the
greatest inhibition of chlamydial entry was observed for those
EBs which expressed Tarp effectors lacking the phosphorylation
domain. These findings strongly support a role for Tarp in
pathogen entry of host cells, and suggests that expression and
delivery of engineered dominant negative mutant effectors may
be employed to attenuate C. trachomatis pathogenesis.
MATERIALS AND METHODS
Organisms and Cell Culture
C. trachomatis serovar L2 (LGV 434) was propagated in HeLa
229 cells (ATCC CCL-2.1) or McCoy B cells (ATCC CRL-
1696) and purified by Renografin density gradient centrifugation
(Scidmore, 2005).
Cloning and C. trachomatis
Transformations
In previous studies we had generated a number of in-frame
Tarp deletions which were expressed as mutant GST-Tarp
fusion proteins from pGEX-6p-1 (GE Health Sciences) plasmids
(Jiwani et al., 2013). Tarp domain deletion mutants included:
phosphorylation domain deletion (1phos; deletion of D125
to Y424), proline rich domain deletion (1PRD; deletion of
S625 to N650), actin binding domain deletion (1ABD; A748
to K758), and F-actin binding domain 1 and 2 deletion (1FAB
1&2; deletion of L871 to G1005). These mutant Tarp alleles
were subcloned into the chlamydial shuttle vector pCtSV.1
in a two-step process. First, wild type Tarp sequence was
amplified from C. trachomatis (LGV 434) genomic DNA (Qiagen
genomic purification kit, Valencia, CA). The forward (5′ACTCC
GCGGTATTGCATTTCTTCACAAACGTTACC-3′) and reverse
(5′TATATACAATTGTTACAGGTCCTCTTCAGATATTAGTT
TTTGTTCTCCTACGGTATCAATCAGTGAGC-3′) DNA
primers (Integrated DNA Technologies, Coralville, IA) were
engineered to amplify 200 bases of putative Tarp promoter
sequence and an in frame 3′ c-myc epitope tag by PCR with SacII
and MfeI linkers. PCR products were purified (Qiagen), digested
with restriction enzymes (New England Biolabs, Beverly, MA)
and cloned into linearized pCtSV.1. This procedure resulted
in the parent pCtSV.Tarp plasmid in which all other plasmids
engineered to express Tarp mutants were generated. pCtSV.Tarp
mutant derivatives were generated by exchanging the mutant
DNA sequence from those pGEX-6p-1 clones described above.
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For example, pCtSV.Tarp1phos resulted from DNA exchange
with digested Tarp DNA sequence flanking the phosphorylation
domain with restriction sites BstAP1 and BmgB1 from pGEX-
6p-1 Tarp1phos. Similarly, the other pCtSV.Tarp mutant clones
were generated albeit with unique restriction enzymes which
flanked the corresponding domain: The proline rich domain
with BmgB1 and Bsm1, the actin binding domain with Bsm1
and Nco1, and the F-actin binding domains 1 and 2 with Nco1
and Mfe1. All engineered vectors were confirmed to be free
of extraneous mutations by DNA sequence analysis and all in
frame domain deletions were verified. All chlamydial shuttle
vectors were purified from E. coli K12 ER2925 cells (New
England Biolabs) and transformed into C. trachomatis (LGV
434) (Wang et al., 2011). All C. trachomatis transformants
were density gradient purified and the number of infectious
(inclusion) forming units (IFUs) was determined by indirect
immunofluorescence of infected host cells with serially diluted
purified elementary bodies (EBs).
Pyrene Assay
Pyrene actin polymerization assays were performed as previously
described (Jiwani et al., 2013). Briefly, monomeric pyrene-labeled
actin was prepared by diluting 100µg of lyophilized pyrene
actin (cytoskeleton Inc. Denver, CO) in 2mL of 5mM Tris
(pH 8.0), 0.2mM CaCl2, 0.2mM ATP (G buffer) and incubated
for 1 h at room temperature, followed by an additional 1 h
incubation at 4◦C. Monomeric pyrene actin was obtained by
collecting the supernatant after a 2 h 100,000× g 4◦C spin in
a Beckman Optima TLX Ultracentrifuge using a TLA 100.3
rotor (BeckmanCoulter). Approximately 20µg of pyrene-labeled
actin was gently mixed with 5µg of GST fusion proteins
in a volume of 500µL for 10min before the addition of
1/20th volume of polymerization buffer (500mM KCl, 20mM
MgCl2, 10mM ATP). The reaction was monitored over 1 h
with an LS 55 Luminescence spectrophotometer directed by
FL WinLab software version 4.0 (Perkin-Elmer, Beaconsfield,
Bucks, United Kingdom) with 2.5-nm bandwidth at 365-
nm excitation wavelength and 2.5-nm bandwidth at 407-nm
emission wavelength.
SDS-PAGE and Immunoblotting
Proteins were separated on SDS 5–15% polyacrylamide gels
(BIORAD, Hercules, CA) and either stained with Imperial
protein stain (Pierce, Rockford, IL) or transferred to 0.45 µm
pure nitrocellulose transfer and immobilization membrane
(Schleicher and Schuell, Keene, NH). Immunoblotting
employed peroxidase conjugated secondary antibodies
(Chemicon International, Temecula, CA) and Supersignal
West Pico chemiluminescent substrate (Pierce). The anti-actin
C4 monoclonal antibody was purchased from Chemicon
International. The anti-actin polyclonal antibody was purchased
from Cytoskeleton, Inc. The anti-phosphotyrosine 4G10
monoclonal antibody was purchased from Upstate (Millipore).
The anti-chlamydial EB polyclonal antibody, the Momp
monoclonal antibody and the GAPDH monoclonal antibody
were all purchased from Pierce. The anti-c-myc monoclonal
antibody was purchased from Genscript (Piscataway, NJ).
The anti-chlamydial Hsp60 A57-B9 monoclonal antibody was
purchased from Thermo Fisher Scientific (Waltham, MA).
Polyclonal rabbit antibodies directed toward C. trachomatis L2
LGV 434 Tarp (CT456) were developed at Rocky Mountain
Laboratories as previously described (Clifton et al., 2004).
Invasion Assay and Indirect
Immunofluorescence Microscopy
Intrinsically fluorescent EBs from C. trachomatis transformants
were purified from cell cultures supplemented with
CellTrackerTM Red CMTPX Dye as previously described
(Carabeo et al., 2007). Briefly, CMPTX-labeled C. trachomatis
EBs (MOI ∼50) were permitted to attach to HeLa 229 host
cells for 30min at 4◦C. HeLa 229 cells were prepared in 24 well
plates with cover slips and grown in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% fetal bovine serum (FBS) and
1% L-glutamine for 24 h prior to infection. The cultures were
rinsed with cold HBSS and the temperature shifted to 37◦C by
the addition of pre-warmed DMEM plus 10% FBS. The cultures
were then incubated at 37◦C for 1 h. The cultures were fixed
with 4% paraformaldehyde at room temperature for 15min and
rinsed with PBS. The cells were not permeabilized. Extracellular
EBs were labeled for 1 h with a monoclonal antibody specific for
chlamydial major outer membrane protein (MOMP). After four
washes in PBS, secondary antibody conjugated to Alexa 488 was
added for 1 h. Coverslips were rinsed and mounted in ProLong
Gold antifade reagent (Invitrogen, Carlsbad, CA). Cells were
examined with a Zeiss Axio Observer A1 microscope equipped
with a phase-contrast and epifluorescence optics. Images were
obtained using an AxioCam MRm camera controlled by Axio
Vision 4.8.2 and further processed using Adobe Photoshop
CS2. The number of green (external) and red (total) EBs was
determined for each host cell. These data were then used to
determine the percentage of internalized EBs. Twenty fields of
view were taken from each cover slip and these percentages were
then averaged together to give a final invasion rate.
Subcellular Fractionation and Protein
Extraction
C. trachomatis infected cells underwent subcellular fractionation
as previously described (Cox and Emili, 2006). Briefly,
C. trachomatis infected McCoy or HeLa 229 cells maintained at
37 or 4◦C or host cells alone incubated at 37◦C were removed
from flasks and suspended in 100mM KCl, 10mM HEPES (pH
7.7), 2mM MgCl2, and 2mM ATP (Buffer A) and disrupted by
sonication delivered in three consecutive 30 s intervals (∼ 2000
joules) using an ultrasonic sonicator processor XL equipped
with a microtip (Misonix Incorporated, Farmingdale, NY). All
cell lysates underwent subcellular fractionation by sequential
centrifugation in which supernatants and pellets were separated.
Lysates were initially subject to an 800× g spin for 15min
at 4◦C. The 800× g supernatants were then subjected to a
10,000× g spin for 30min at 4◦C. The remaining 10,000×
g supernatant underwent a 100,000× g spin for 1 h at 4◦C.
Protein sample buffer was added to all pellets and supernatants
and proteins were resolved by SDS-PAGE and transferred to
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nitrocellulose membranes for immunoblotting with antibodies
specific for c-myc, Tarp, actin, GAPDH, Momp, and chlamydial
EBs. Subcellular fractionation experiments were conducted in
both McCoy (Figure 6) and HeLa 229 (Supplemental Figure 1)
cells.
C. trachomatis Development
HeLa 229 cells were seeded into 6 well plates (2 × 105 cells/well)
and grown in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% fetal bovine serum (FBS) and 1% L-glutamine for
24 h. Individual wells were infected with wild type C. trachomatis
L2 (LGV 434) or C. trachomatis transformants. All host cells and
bacteria were collected from select wells (cells scraped off the
bottom of each well and collected in 15mL tubes, and sonicated
for 30 s using a microtip equipped Misonix sonicator) at 0, 12,
24, 36, and 48 h. Cell lysates were then frozen at −80◦C until
all time points had been collected. Cell lysates were thawed
on ice and diluted and then placed onto HeLa cells grown
on 16mm circular cover slips contained within 24 well plates
and grown in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and 1% L-
glutamine. After a 40 h incubation, infected cells were then
immunostained and observed under a fluorescent microscope for
inclusion formation. Twenty fields of view were taken from each
cover slip (the experiment was performed in triplicate) and cover
slip counts were averaged. Averages were plotted using GraphPad
Prism software.
RESULTS
Mutant Tarp Proteins Diminish the Ability
Of Wild Type Tarp to Polymerize Actin
Filaments
The Tarp actin binding domain (ABD, amino acids 748–758)
and the proline rich polymerization domain (PRD, amino acids
625–650) have previously been found to be required for Tarp
mediated polymerization of pyrene actin in vitro (a summary
of Tarp protein domains is provided in Figure 1; Jewett et al.,
2006). One model for Tarp mediated actin nucleation advocates
that Tarp oligomerizes via the proline rich domain. Tarp effectors,
which come together following secretion into the host cell
cytosol, associate with monomeric actin to form an actin nucleus,
affectedly reducing the critical concentration of actin required
for actin filament formation (Jewett et al., 2006). Since Tarp
is hypothesized to function in a homo-oligomeric complex,
we tested whether Tarp1PRD and Tarp1ABD were able to
disrupt wild type Tarp mediated actin polymerization in a
dominant negative fashion. To investigate whether mutant Tarps
could inhibit actin polymerization induced by wild type Tarp,
purified recombinant wild type Tarp proteins and Tarp1ABD or
Tarp1PRDwere combined at equal molar ratios and analyzed for
actin nucleation in pyrene actin polymerization assays (Figure 2).
Similar to our previous findings, when Tarp1PRD or Tarp1ABD
alone was introduced to pyrene actin, an increase in the rate of
actin polymerization was not observed compared to actin alone
FIGURE 1 | Schematic of Tarp protein mediated signaling pathways implicated in chlamydial entry and development. C. trachomatis Tarp harbors an
N-terminal tyrosine rich repeat phosphorylation domain (Y, green box). Tyrosine residues are phosphorylated by members of the Src family kinases (SFKs) such as Src,
Yes and Fyn and by other tyrosine kinases, Syk and Abl/Arg kinases. The actin nucleating activity of Tarp results from distinct G-actin binding (red box) and proline rich
(blue box) oligomerization domains and from an Arp2/3-dependent pathway resulting from the recruitment and activation of host cell signaling proteins Vav2, Sos1,
Eps8, Abi1, Rac1, and WAVE2. Tarp also harbors two F-actin binding domains (FAB 1 and 2: yellow and pink boxes) that are implicated in the formation of actin
bundles. Phosphorylated Tarp can also associate with the host cell Src homology 2 domain containing protein 1 (SHC1) and the phosphoinositide 3-kinase (PI3K),
which are implicated in altering the activation state of host signaling proteins to create a protective niche for the developing bacterium.
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FIGURE 2 | Tarp mutants inhibit the ability of wild type Tarp to nucleate actin in vitro. (A) Purified Tarp and Tarp mutants harboring deletions in the proline rich
oligomerization domain (1 PRD) and the actin binding domain (1 ABD). Proteins were resolved by SDS-PAGE and visualized by Coomassie blue staining. (B) The
Tarp 1PRD deletion mutant inhibits wild type Tarp mediated actin nucleation in pyrene actin nucleation assays as observed by a decrease in the slope of the pyrene
assay. Equal concentrations of proteins described in (A) were incubated with 1µM monomeric pyrene-labeled actin. An increase in actin polymerization after the
addition of polymerization buffer at 300 s was measured as arbitrary fluorescence intensity [Intensity (a.u.)] over time [Time(s)]. Pyrene actin alone served as a negative
control. (C) The Tarp 1ABD deletion mutant also interferes with wild type Tarp mediated actin nucleation in pyrene actin nucleation assays. The experiment was
designed as described in (B). using Tarp 1ABD. (D) Purified Tarp (as in A) and a Tarp mutant harboring a deletion in the tyrosine rich phosphorylation domain (1phos).
Proteins were resolved by SDS-PAGE and visualized by Coomassie blue staining. (E) The Tarp1phos deletion mutant enhances wild type Tarp mediated actin
nucleation in a pyrene actin nucleation assay as an increase in the slope in the pyrene actin assay was observed. The pyrene curve generated by Tarp 1phos and wild
type Tarp was equivalent to a 2× concentration of wild type Tarp curve (data not shown) (experiment was performed similar to B,C). The pyrene actin polymerization
assays are representative of three repeated experiments.
controls (Figures 2B,C). The amount of Tarp1PRD employed
in these experiments was lower compared to previous studies
to ensure that Tarp1PRD would not appreciably sequester
monomeric actin (Jiwani et al., 2013). At higher concentrations,
Tarp1PRD sequesters monomeric actin and may disrupt native
Tarp function by lowering the concentration of available actin
in the reaction. As predicted, when (Tarp1PRD or Tarp1ABD)
were mixed with an equal amount of wild type Tarp, the rate
of actin polymerization was reduced (Figures 2B,C). Although
the rate of pyrene actin polymerization was reduced in the
presence Tarp1PRD or Tarp1ABD, some Tarp mediated actin
nucleation was still observed. To confirm that the reduction of
actin polymerization was not the consequence of steric hindrance
caused by excess Tarp in the reaction, an additional control
(Tarp1phos) which is not predicted to interfere with actin
polymerization was tested. Tarp which lacks the tyrosine rich
phosphorylation domain (Tarp1phos, harbors the deletion in
amino acids 125–424) has previously been shown to nucleate
actin to equivalent rates as compared to wild type Tarp
(Jiwani et al., 2013). To test whether Tarp mediated actin
polymerization might be affected by Tarp1phos (Figure 2D),
purified Tarp and Tarp1phos were mixed at equal molar ratios
and tested in pyrene actin polymerization assays. Tarp1phos
combined with wild type Tarp enhanced the rate of actin
polymerization due to the two-fold molar increase of functional
actin nucleators (Figure 2E). These data support the hypothesis
that biochemically wild type Tarp may experience reduced actin
polymerization kinetics when associated with or competing
with defective Tarp1PRD or Tarp1ABD. Conversely, wild
type Tarp mediated actin polymerization is not inhibited by
Tarp1phos.
C. trachomatis Transformants are Able to
Express Epitope Tagged Wild Type and
Mutant Tarp Effectors
In order to determine whether mutant Tarp effectors might
disrupt endogenous Tarp function in vivo, we engineered a
chlamydial shuttle vector to express epitope tagged wild type
and mutant Tarp effectors (Figure 3A). C. trachomatis genes
are temporally regulated so as to match their function with
the correct window in the chlamydial developmental cycle.
To promote coordinated expression of the mutant Tarp alleles
with that of the endogenous Tarp gene, mutant Tarp effectors
expressed from the chlamydial shuttle vector were engineered
under the control of ∼200 nucleotides of DNA upstream of the
annotated Tarp gene, which we have termed the Tarp promoter
(tarPp) (Figure 3). Mutant Tarp constructs included deletions of
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FIGURE 3 | Schematic diagram of the chlamydial shuttle vector pCtSV.1 and the derivatives engineered to express epitope tagged Tarp mutants. (A)
The C. trachomatis shuttle vector pCtSV.1 was adapted to allow for the expression of c-myc tagged Tarp under the control of the tarP promoter (tarPp). In frame
deletions were generated in the tarP gene to remove the phosphorylation domain (pCtSV.Tarp1phos), proline rich domain (pCtSV.Tarp1PRD), g-actin binding domain
(pCtSV.Tarp1ABD) f-actin binding domains (pCtSV.Tarp1FAB1 and 2), and the double deletion mutant, a phosphorylation domain and proline rich domain mutant
(pCtSV.Tarp1phos1PRD) respectively. (B) Transformed C. trachomatis express epitope tagged Tarp. Protein lysates were generated from McCoy cells infected with
C. trachomatis L2 transformed with the shuttle vector pCtSV.1, pCtSVTarp, pCtSV.Tarp1phos, pCtSV.Tarp1PRD, pCtSV.Tarp1ABD, and pCtSV.Tarp1FAB1and2 (the
shuttle vectors depicted in A). Protein samples were resolved by SDS-PAGE and transferred to nitrocellulose membranes for immunoblot analysis with Tarp (α Tarp)
and c-Myc (α c-myc) specific antibodies. Molecular mass is in kiloDaltons (kDa). (C) C. trachomatis (+pCtSV.Tarp) Infected host cells were collected from a 6 well plate
at 6, 12, 24, and 48 h post infection and solubilized in protein sample buffer. Protein samples were resolved by SDS-PAGE and transferred to nitrocellulose
membranes for immunoblot analysis with Tarp (α Tarp) and c-Myc (α c-myc) specific antibodies.
the phosphorylation domain, the proline rich domain, the actin
binding domain and a Tarp truncation which resulted in the
deletion of the F-actin binding domains 1 and 2 (Figure 3A).
C. trachomatis L2 transformed with each shuttle vector were
expanded under antibiotic selection for several passages, density
gradient purified and tested for the presence of the c-myc
epitope tag by western blot analysis. All of the transformants
produced c-myc tagged proteins of the expected size (Figure 3B).
Interestingly, endogenous Tarp in C. trachomatis expressing
Tarp1phos appears to be lower compared to the relative
abundance of Tarp in the other transformants. This may hold
true for the other transformants (ABD, PRD, and FAB1 and 2)
but cannot be visualized in the western analysis since mutant
and endogenous Tarp migrate to the same position on the
protein gels.
C. trachomatis Transformants Expressing
Mutant Tarp Effectors are Inhibited in
Bacterial Invasion of Host Cells
We hypothesized that production of a dominant negative Tarp
complex in vivo would have a significant effect on the ability
of elementary bodies to invade host cells. To test the invasion
potential of the five different C. trachomatis clones expressing
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FIGURE 4 | C. trachomatis transformants harboring epitope tagged
mutant Tarps are deficient in chlamydial entry. (A) Wild type C.
trachomatis (L2; circles) or L2 transformants harboring plasmid pCtSV.Tarp
(+ pCtSV.Tarp; squares), pCtSV.Tarp1phos (+ pCtSV.Tarp1phos; triangles),
pCtSV.Tarp1PRD (+ pCtSV.Tarp1PRD; inverted triangles), pCtSV.Tarp1ABD
(+ pCtSV.Tarp1ABD; asterisks), or pCtSV.Tarp1FAB1and2
(+ pCtSV.Tarp1FAB1and2; “x”), were examined for chlamydial invasion of
HeLa 229 cells. Intrinsically fluorescent cell tracker (CMPTX) labeled EBs were
used in invasion assays. After allowing 1 h for invasion, extracellular EBs were
counterstained by indirect immunofluorescence with a monoclonal antibody to
C. trachomatis L2 MOMP and a goat anti mouse antibody conjugated to Alexa
488. The data are represented as the percentage of intracellular EBs relative to
the total number of extracellular and intracellular EBs per field of view. The data
represented from two biological replicates are shown. Each data point
represents a single field of view at 1000× magnification. Data sets were
compared with one way ANOVA and Tukey’s multiple comparison test of the
mean. ***represents a p < 0.001. (B) Development of wild type C. trachomatis
L2 (circles) and transformants harboring plasmid pCtSV.Tarp (+ pCtSV.Tarp;
squares), pCtSV.Tarp1phos (+ pCtSV.Tarp1phos; triangles), after normalizing
the initial multiplicity of infection for each clone (IFU normalization was
confirmed by determining the number of inclusions formed at time zero).
Infected cells with antibiotic selection (filled symbols) and infected cells without
antibiotic selection (open symbols) were collected at t = 0, 12, 24, 36, and
48 h post infection and mechanically lysed to release infectious EBs. Inclusion
forming units (IFUs) were determined for each transformant by serial dilution of
released EBs harvested at each time point and reinfection of HeLa cells grown
on coverslips to determine the number of inclusion forming units per mL of
harvested material.
mutant Tarp effectors from the C. trachomatis shuttle vector,
we performed invasion assays to quantitate the number of
elementary bodies which entered a host cell in a 1 h time period
(Figure 4A). As predicted, C. trachomatis expressing Tarp
lacking the actin binding domain (Tarp1ABD) demonstrated a
significant reduction in host cell invasion compared to wild type
C. trachomatis L2 and C. trachomatis harboring pCtSV.Tarp.
Surprisingly and in contrast to the in vitro actin polymerization
studies, C. trachomatis expressing Tarp1phos displayed a
significant reduction in invasion relative to all of the clones
analyzed, including C. trachomatis expressing Tarp1ABD
(Figure 4A). No altered invasion phenotype was observed for
C. trachomatis expressing Tarp1PRD or Tarp1FAB1 and 2. In
order to examine if the presence of a dominant-negative Tarp
might disrupt chlamydial development, growth curves were
performed for C. trachomatis expressing Tarp1phos and wild
type controls (Figure 4B). No significant changes to chlamydial
growth was observed between wild type and C. trachomatis
expressing Tarp1phos as measured by the number of EBs
harvested from infected cells at 0, 12, 24, 36, and 48 h post
infection (Figure 4B and data not shown).
C. trachomatis Expressing Tarp1phos
Demonstrate Reduced Phosphorylation of
Endogenous Tarp
We hypothesized that C. trachomatis expressing Tarp1phos
might show a reduction in endogenous Tarp phosphorylation
following attachment and entry into host cells as Tarp1phos is
likely to compete with endogenous Tarp for translocation
into the host cell. Tarp1phos is missing the tyrosine
residues known to be phosphorylated by Src family
kinases (SFKs) therefore Tarp1phos is not expected to
be phosphorylated by host cell tyrosine kinases after
translocation into the host cell. In order to test this,
wild type C. trachomatis or C. trachomatis harboring the
plasmids presented in Figure 3 were added to host cells and
protein lysates were generated at 0 and 1 h post infection.
Tarp has previously been identified as the predominant
phosphotyrosine modified protein of ∼150 kDa which
is observed in the wild type C. trachomatis infected cells.
Interestingly, phosphorylated Tarp was reduced in those bacteria
expressing Tarp1phos, but not in the other transformants
(Figure 5).
C. trachomatis is Able to Translocate
Tarp1phos into the Host Cells
C. trachomatis expressing both endogenous Tarp and Tarp1phos
demonstrated a reduction in host cell invasion and Tarp
phosphorylation. These results raised the possibility that type
three secretion is altered and/or inhibited in C. trachomatis
expressing Tarp1phos. To determine whether C. trachomatis
expressing Tarp1phos was capable of type three secretion we
examined whether endogenous Tarp and plasmid encoded
epitope tagged Tarp1phos could be recovered from the
soluble fraction following subcellular fractionation of host cells
(Figure 6A). The fractionation profile of wild type C. trachomatis
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FIGURE 5 | C. trachomatis expressing Tarp1phos exhibit reduced levels of tyrosine phosphorylation during entry. Wild type C. trachomatis (WT L2) or L2
transformants harboring plasmids pCtSV.Tarp pCtSV.Tarp1phos, pCtSV.Tarp1PRD, pCtSV.Tarp1ABD or pCtSV.Tarp1 FAB1and2 were used to infect McCoy host
cells for 1 h. Mock treated host cells (No EBs) served as a negative control. Infected host cells were collected from a 6 well plate at 0 and 1 h post infection and
solubilized in protein sample buffer. Protein samples were resolved by SDS-PAGE and transferred to nitrocellulose membranes for immunoblot analysis with
phosphotyrosine (α Y-PO4), chlamydial heat shock protein 60 (α Hsp60), Tarp (α Tarp) and actin (α actin) specific antibodies. The infection and subsequent
phosphorylation western blot assay presented is representative of three repeated experiments.
infected cells is presented as Supplemental Figure 1 for
reference. Endogenous Tarp and epitope tagged Tarp1phos
can be distinguished by their unique molecular weights and
the presence or absence of the c-myc epitope tag (Figure 3).
Protein supernatant samples sequentially obtained from 800,
10,000, and 100,000× g centrifugal spins indicated that the
endogenous Tarp and Tarp1phos effectors co-fractionated and
were detectable in fractions that were distinct from intact EBs,
which pellet at 10,000× g (Figure 6B). The endogenous Tarp
and Tarp1phos proteins were observed in the 100,000× g
pellet and the 100,000× g soluble fraction, the latter represents
the host cell cytosolic fraction as defined by the presence
of the soluble eukaryotic protein GAPDH (Figure 6B). We
hypothesize that most of the secreted tarp is restricted to the
100,000× g pellet due to interactions with actin filaments
(short actin filaments pellet at 100,000× g). The portion of
Tarp found in the 100,000× g supernatant (soluble fraction)
may represent those proteins which have not yet associated
with host cell molecules of the cytoskeleton. Non-secreted
chlamydial antigens identified by the anti-EB and anti-MOMP
antibodies were not detected in fractions beyond the 10,000×
g pellet, indicating that these later protein fractions did not
contain lysed EBs. It has been shown previously that type
three secretion by C. trachomatis is temperature dependent
and can be inhibited at low temperatures (Jamison and
Hackstadt, 2008). Consistent with this finding, endogenous
and mutant Tarp were not detected in the host cell cytosolic
fraction of host cells maintained at 4◦C during the course
of the C. trachomatis infection. Together these data indicate
that C. trachomatis expressing Tarp1phos is capable of type
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FIGURE 6 | C. trachomatis transformants demonstrate secretion of both wild type Tarp and epitope tagged mutant Tarp1phos. (A) The schematic of the
differential centrifugation steps and the supernatants (sup) and pellets recovered from centrifugation at 800, 10,000, and 100,000× g. Secreted effector proteins such
as Tarp are expected to be detectable in the bacteria-free 100,000 × g pellet (microsomes) and soluble fractions. (B) Subcellular fractionation of C. trachomatis
infected cells by differential centrifugation out to 100,000× g yields a soluble Tarp fraction that is distinct from intact elementary bodies. Total lysates derived from
McCoy host cells infected with C. trachomatis serovar L2 transformed with the shuttle vector pCtSV.Tarp1phos (L2 pCtSV.Tarp1phos) underwent subcellular
fractionation by centrifugation. Fractions were resolved by SDS-PAGE and transferred to nitrocellulose for immunoblot analysis with antibodies specific for
phosphotyrosine (α Y-PO4), Tarp (α Tarp), c-Myc epitope (α c-myc), elementary bodies (α EB), C. trachomatis major outer membrane protein (α Momp),
Glyceraldehyde 3-phosphate dehydrogenase a soluble protein marker (α GAPDH) and actin a protein expected to be present in all fractions (α actin). The infection and
subsequent cell fractionation data presented is representative of three repeated experiments.
three secretion mediated delivery of endogenous and mutant
Tarp into the host cell cytosol. Although the data presented
in Figure 6B do not provide quantitative measures of WT
and Tarp1phos secretion, the experiment indicates that both
endogenous and Tarp1phos are actively secreted into the
host cell.
Dissociation of Tarp1phos from the Native
Tarp Effector is Able to Restore
C. trachomatis Invasion of Host Cells
Previous studies with purified recombinant Tarp effectors
revealed that Tarp multimerization is mediated by a region of
∼25 amino acids rich with prolines subsequently called the
proline rich domain (PRD) (Jewett et al., 2006). This model
suggests that plasmid encoded Tarp1phos and endogenous
Tarp may associate following translocation into the cell perhaps
resulting in the observed dominant-negative invasion phenotype.
To further test this hypothesis, we sought to disrupt the
ability of Tarp1phos to form heteromeric complexes with
wild type Tarp through genetic deletion of the proline rich
domain from the pCtSV Tarp1phos construct. According to
our model, a Tarp1phos1PRD double mutant lacking both the
phosphorylation domain and the proline rich oligomerization
domain would be unable to associate with endogenous Tarp,
rescuing the dominate negative phenotype caused by the
Tarp1phos protein. As predicted, C. trachomatis transformants
harboring pCtSVTarp1phos1PRD demonstrated wild type
levels of chlamydial entry after 1 h (80% internalized EBs) and
displayed no defect in chlamydial growth (Figure 7 and data not
shown).
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FIGURE 7 | Introduction of a second protein domain deletion within
Tarp1phos disrupts the dominant negative phenotype. Since the proline
rich domain (PRD) is implicated in Tarp oligomerization, a PRD domain deletion
was introduced into the pCtSV.Tarp1phos shuttle vector creating
pCtSV.Tarp1phos1PRD which is engineered to express an epitope tagged
double mutant Tarp1phos1PRD. (A) Protein samples were resolved by
SDS-PAGE and transferred to nitrocellulose membranes for immunoblot
analysis with Tarp (α Tarp) and c-Myc (α c-myc) specific antibodies. Molecular
mass is in kiloDaltons (kDa). (B) As described previously, C. trachomatis
transformants were examined for bacterial invasion of host cells. EBs were
examined for chlamydial invasion of HeLa 229 cells. Intrinsically fluorescent cell
tracker (CMPTX) labeled EBs were used in invasion assays. After allowing 1 h
for invasion, extracellular EBs were counterstained by indirect
immunofluorescence with a monoclonal antibody to C. trachomatis L2 MOMP
and a goat anti mouse antibody conjugated to Alexa 488. The data are
represented as the percentage of intracellular EBs relative to the total number
of extracellular and intracellular EBs per field of view. The data from two
biological replicates are shown. Each data point represents a single field of
view at 1000× magnification.
DISCUSSION
Obligate intracellular pathogens such as C. trachomatis harbor
unique tools to hijack host cell processes, promoting bacterial
replication and immune evasion. The Tarp effector is a candidate
virulence factor that is hypothesized to trigger host cell entry
and other host signaling events to promote pathogen invasion.
By leveraging our understanding of the biochemical features of
the Tarp polypeptide, we now demonstrate that mutant Tarp
effectors can be engineered to disrupt pathogen entry of host
cells in a dominant-negative manner. The interplay between the
host and the pathogen is intricate and involves mechanisms of
pathogen-targeted disruption of host cellular processes, which
are only partially understood (Ribet and Cossart, 2015). To some
degree, C. trachomatis execute cellular override mechanisms by
delivering bacterial effector proteins into the host cell cytosol
via a type three secretion apparatus (Ferrell and Fields, 2016).
Consequentially, a number of studies have focused on how
Tarp is able to associate with host cell actin, tyrosine kinases,
and SH2 domain containing proteins (Jewett et al., 2006, 2008;
Lane et al., 2008; Mehlitz et al., 2008, 2010; Lutter et al., 2010;
Jiwani et al., 2012, 2013). Tarp is a large protein consisting of
1005 amino acids and is, biochemically speaking, one of the
most well characterized C. trachomatis effectors (Mueller et al.,
2014). Host cytoskeletal rearrangements are required for bacterial
invasion of host cells and it is believed thatC. trachomatis actively
directs this process, mediated in part by Tarp translocation
into the host cell. Recombinant Tarp by itself is a potent
nucleator of actin and dramatically increases the rate of actin
polymerization compared to actin alone controls in in vitro
pyrene actin polymerization assays (Jewett et al., 2006). Domain
deletion analysis has revealed the minimum protein sequence
required for actin binding and actin nucleation (Jewett et al.,
2006). These studies demonstrated that Tarp mediated actin
nucleation is predominantly driven by Tarp oligomerization,
which could make this biochemical function amenable to
interference or disruption if the Tarp complex failed to assemble
appropriately in vivo (Jewett et al., 2006). With the advent of
a chlamydia transformation system (Wang et al., 2011), it was
now possible to genetically manipulate C. trachomatis to express
plasmid-encoded mutant Tarp effectors engineered to disrupt
endogenous Tarp-mediated actin nucleation. As hypothesized,
C. trachomatis producing a mutant Tarp effector, which lacked
the actin binding domain required for actin nucleation, resulted
in disruption of chlamydial entry into host cells. These findings
were consistent with the ability of purified Tarp1ABD protein
to reduce the actin nucleation activity of purified wild type Tarp
protein in vitro. Together these data suggest that C. trachomatis
producing both endogenous Tarp and Tarp1ABD protein have
a diminished ability to nucleate actin resulting in reduced host
cell invasion. Conversely, C. trachomatis harboring mutant Tarp
effectors lacking the proline rich domain required for Tarp
oligomerization did not disrupt bacterial entry. This may not
be surprising as Tarp1PRD is predicted to lack the ability
to associate with endogenous Tarp and therefore is not likely
to disrupt the homomeric complex critical for Tarp function.
Purified Tarp1PRD alone can sequester monomeric actin in
a concentration dependent manner in vitro (Figure 2B; Jiwani
et al., 2013). The lower rate of actin polymerization observed
for the combination of purified Tarp1PRD and purified wild
type Tarp in vitro may be the result of reduced monomeric
actin available in the pyrene assay due to sequestration of
monomeric actin by Tarp1PRD protein. Although it remains
a possibility that Tarp1PRD produced by the C. trachomatis
pCtSVTarp1PRD clone is able to sequester monomeric actin in
vivo, this ability does not result in a measurable change in host
cell invasion.
Interestingly, the greatest inhibition of EB entry of host cells
was observed for C. trachomatis transformants which expressed
Tarp1phos. Based on our in vitro pyrene actin polymerization
assays it is unlikely that Tarp1phos is disrupting the direct actin
nucleation activity of endogenous Tarp. Tarp phosphorylation
has been implicated in host cell signaling via SH2 domain
containing host cell proteins that promote the activation of other
host cell actin nucleators such as the Arp2/3 complex (Lane et al.,
2008; Mehlitz et al., 2010). Therefore, a heterocomplex between
Tarp1phos and endogenous wild type Tarp may indirectly
disrupt actin nucleation as a result of altered host cell signaling.
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Previous experiments have indicated that phosphorylated Tarp is
unable to active the Arp2/3 complex directly and that any host
cell signaling cascades that may be initiated by phosphorylated
Tarp also requires activation of nucleation promoting factors
(NPFs) such as WASP/N-WASP (Jiwani et al., 2012). Despite the
compelling biochemical evidence for the indirect contribution
of Tarp phosphorylation to actin polymerization and host cell
entry, the role for Tarp phosphorylation in C. trachomatis
invasion remains unclear. In contrast to the invasion phenotype
conferred by C. trachomatis expressing Tarp1phos, it has been
shown that inhibition of Tarp phosphorylation via tyrosine
kinase inhibitors such as PP2 does not significantly inhibit C.
trachomatis entry into host cells (Jewett et al., 2008). A key
difference between these two studies is the chemical inhibition
of phosphorylation of full length endogenous Tarp versus
phenotypic analysis of C. trachomatis transformants harboring
Tarp molecules which are missing the phosphorylation domain.
It is therefore possible that the tyrosine rich repeat region is not
only important for Tarp phosphorylation, but has an additional
undescribed role in EB entry. The data presented herein suggest
that the presence of Tarp1phos has altered endogenous Tarp
function leading to reduced C. trachomatis invasion or that
Tarp1phos has disrupted EB entry independently. We found
no evidence for significantly altered levels of Tarp secretion as
our cell fractionation experiments revealed that both endogenous
Tarp and Tarp1phos were isolated from the soluble fractions
containing the host cell cytosol alone. Although it remains to
be seen if subtle quantitative differences in Tarp concentration
or in secretion relative to wild type may have a profound
effect on bacterial invasion. Previous reports have demonstrated
that Tarp secretion is mediated by the chlamydial chaperone
Slc1 (Brinkworth et al., 2011). Slc1 and Tarp associate via
the N-terminal domain of Tarp mapped to amino acids
1–200. Interestingly, Tarp1phos lacks amino acids 125–424 and
was still capable of translocation into the host cell, therefor
Tarp1phos further delineates the region required for T3SS-
mediated secretion of Tarp.
Tarp proteins form oligomeric complexes in vitro which are
mediated by the proline rich domain. In support of this model,
deletion of the proline rich domain from the Tarp1phos protein
restored EB invasion to wild type levels. Tarp phosphorylation
is implicated in host cell signaling; although these signaling
mechanisms have not previously been experimentally defined to
be directly associated with entry, our data now suggest that the
Tarp tyrosine rich sequence that comprises the phosphorylation
domain itself is important for entry.
Analysis of Tarp orthologs from different chlamydial species
and serovars has revealed conserved biochemical features such
as the ability to bind and nucleate actin albeit by engaging
slightly different mechanisms (Jewett et al., 2010). Conversely,
many unique characteristics, such as C. trachomatis L2 Tarp
phosphorylation or C. caviae strain GPIC Tarp’s ability to bind
to focal adhesion kinase (FAK) reveal that Tarp orthologs may
have evolved to serve specific functions for unique human versus
animal hosts (Clifton et al., 2005; Thwaites et al., 2014). The
ability to introduce Tarp deletion mutants into C. trachomatis is
the first step toward defining which protein domains may play
a dominant role in vivo. This work may be expanded in the
future to include analysis of other Tarp orthologs as well as the
generation of a Tarp null or a conditional knockout.
A mechanistic understanding of chlamydial entry of host cells
will likely lead to novel interventions that prevent C. trachomatis
infections. Many questions still remain, but this work represents
the first instance of the in vivo analysis of the Tarp effector
and its functional domains within EBs and the utilization of
dominant negative mutant alleles to disrupt chlamydial invasion
of host cells.
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Supplementary Figure1 | Subcellular fractionation of wild type
C. trachomatis infected cells yields a phosphorylated Tarp fraction
distinct from intact elementary bodies. HeLa 229 cells infected with wild type
C. trachomatis serovar L2 (L2) underwent subcellular fractionation by
centrifugation of lysed cells (total lysate). Lysate pellets were sequentially obtained
from 800, 10,000, and 100,000 × g spins leaving a 100,000 × g supernatant
(soluble fraction) Fractions were resolved by SDS-PAGE and transferred to
nitrocellulose for immunoblot analysis with antibodies specific for phosphorylated
tyrosines (α Y-PO4), Tarp (α Tarp), elementary bodies (α EBs) Glyceraldehyde
3-phosphate dehydrogenase (α GAPDH), actin (α actin), lysosome associated
membrane protein 1 (α Lamp1) and Phosphoinositide 3-kinase (α PI3K).
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